Pluri Inc., a biotechnology company, focuses on the development of placenta-based cell therapy product candidates for the treatment of multiple inflammatory, mu…
$1.05-3.67%
报价 2026-11-13
市值
$11.3M
EV
$43.5M
PE (TTM)
–
预期 PE
–
52 周区间距高点 -73.1%
$0.85$3.90
筛选结果
pipeline · 2026-11-13Filter✗ 高增长✗ Cheap✗ GARP
excluded industry: Biotechnology
研究结论
还没有研究记录。先生成 L2 基本面报告(约 1–3 分钟),结论会显示在这里。
去生成基本面报告 →历史股价
加载中…
事件
0 条 · 随区间与图例筛选该区间内无事件。
同行对比
同行业市值相近 · Biotechnology| 公司 | 市值 | 今日 | 预期营收增速 | 毛利率 | PE | EV/EBITDA | P/FCF | 池 |
|---|---|---|---|---|---|---|---|---|
| PLURPluri Inc. | $11.3M | -3.7% | – | 44.6% | – | – | – | |
| PLRZPolyrizon Ltd. | $12.4M | -3.7% | – | 0% | – | – | – | |
| GUTSFractyl Health, Inc. Common Stock | $12M | +11.3% | +153.1% | 0% | – | – | – | |
| BOLTBolt Biotherapeutics, Inc. | $11.7M | +2.9% | -66.1% | 95.7% | – | – | – | |
| CLRBCellectar Biosciences, Inc. | $11.4M | -1.7% | -74.7% | 0% | – | – | – | |
| PTNPalatin Technologies, Inc. | $11.1M | -5.2% | +104.6% | 99.6% | – | – | – | |
| HINDVyome Holdings, Inc. | $11.1M | -3.1% | +50.0% | 9% | – | – | 21.1x | |
| LSTALisata Therapeutics, Inc. | $10.9M | -5.5% | 0.0% | 95% | – | – | – | |
| KZIAKazia Therapeutics Limited | $10.7M | -4.7% | – | 100% | – | – | – | |
| 同行中位数 | – | – | +25.0% | 52% | – | – | 21.1x |
研究全文
L2 基本面 memo
尚无基本面 memo
点击「生成基本面报告」——基于最新 filings、电话会纪要与分析师共识生成 L2 memo。
财务报表
暂无季度数据(首次研究运行后填充)。